|
【结 构 式】 
|
【药物名称】MLD-987, SDZ-MLD-987 【化学名称】(1R,9S,12S(1'R,3'R,4'R),13R,14S,17R,21S,23S,24R,25S,27R)-17-Allyl-1,14-dihydroxy-23,25-dimethoxy-12-[2-[3-methoxy-4-[N-[4-(2-methoxy-2-oxoethyl)phenyl]carbamoyloxy]cyclohexyl]-1(E)-methylvinyl]-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(4,9)]octacos-18(E)-ene-2,3,10,16-tetraone 【CA登记号】183473-57-6 【 分 子 式 】C54H78N2O15 【 分 子 量 】995.22816 |
【开发单位】Novartis (Originator) 【药理作用】Asthma Therapy, IMMUNOMODULATING AGENTS, Immunosuppressants, RESPIRATORY DRUGS |
合成路线1
The title carbamate was prepared by treatment of the ascomycin derivative (I) with triphosgene and dimethylaminopyridine at -77 C, followed by condensation of the intermediate chloroformate (II) with methyl 4-aminophenylacetate (III).
| 【1】 Naef, R.; Hersperger, R. (Novartis AG; Novartis Deutschland GmbH); Ascomycins. JP 2000505044; US 5925649; WO 9631514 . |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 47057 | (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-17-allyl-1,14-dihydroxy-12-[(E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-23,25-dimethoxy-13,19,21,27-tetramethyl-11,28-dioxa-4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene-2,3,10,16-tetrone | C44H69NO12 | 详情 | 详情 | |
| (II) | 47058 | (1R,9S,12S,13R,14S,17R,21S,23S,24R,25S,27R)-17-allyl-12-((E)-2-[(1R,3R,4R)-4-[(chlorocarbonyl)oxy]-3-methoxycyclohexyl]-1-methylethenyl)-1,14-dihydroxy-23,25-dimethoxy-13,19,21,27-tetramethyl-2,3,10,16-tetraoxo-11,28-dioxa-4-azatricyclo[22.3.1.0(4,9)]octacos-18-ene | C45H68ClNO13 | 详情 | 详情 | |
| (III) | 47059 | methyl 2-(4-aminophenyl)acetate | C9H11NO2 | 详情 | 详情 |
Extended Information